Eli Lilly guides 2026 profit and sales above estimates as obesity-drug demand stays hotWhat happenedEli Lilly ($LLY) reported a strong Q4 and guided 2026 EPS to roughly $33.50–$35 and sales to about $80B–$83B, both ahead of consensus. Demand for Mounjaro and Zepbound is still driving big volume growth, and Lilly thinks it can absorb pricing pressure with scale, direct-to-consumer momentum, and more supply. Lilly’s oral obesity pill (orforglipron) with an FDA decision expected in April.Why traders care1. It reinforces “GLP-1 winners keep winning” and resets expectations for the obesity market in 2026.2. It pressures competitors on pricing and access (cash-pay and discount programs matter more).3. It pulls the whole supply chain (fill-finish, packaging, tools) into focus as volume keeps climbing.WinnersGLP-1 leaders and obesity-drug revenue leverageStrong guidance and sustained demand support higher earnings power, and the market tends to reward the leaders with scale, supply, and commercial execution.Names: $LLY (Eli Lilly), $NVO (Novo Nordisk)Drug manufacturing tools and capacity enablersMore GLP-1 volume means more spend on manufacturing scale-up, quality systems, and process equipment across the biopharma production stack.Names: $TMO (Thermo Fisher), $DHR (Danaher)High-volume injectable packaging and delivery componentsPens, syringes, elastomers, stoppers, and containment systems can see steady demand as weekly injectables remain the dominant format and volumes rise.Names: $WST (West Pharmaceutical Services), $BDX (Becton Dickinson)LosersWeight-loss also-rans and pricing-takersWhen the category leaders guide strong and lean into cash-pay pricing, competitors can be forced into deeper discounts and weaker 2026 outlooks.Names: $NVO (Novo Nordisk), $VKTX (Viking Therapeutics)“Eat-more” consumer categories exposed to appetite suppression narrativesEven if the real-world impact is gradual, the market often trades the perception that GLP-1 adoption pressures calorie-dense foods, snacks, and quick-service demand.Names: $MCD (McDonald’s), $PEP (PepsiCo)Bariatric and weight-management procedure ecosystemIf medical weight loss keeps gaining share, it can create headline risk for procedure volumes and related elective demand assumptions.Names: $SYK (Stryker), $MDT (Medtronic)What to watch next* April FDA decision window for Lilly’s oral obesity pill (orforglipron): positive read-through could extend “leader premium” for $LLY.* Pricing headlines: more cash-pay discounts or payer pushback can swing the whole group quickly.* Supply updates: any hints of constraint easing (or new bottlenecks) will move the tools and packaging names.#StockMarket #Trading #Investing #DayTrading #SwingTrading #Healthcare #Biotech #Pharma #Earnings #GLP1 #WeightLoss #Obesity #LLY #NVO #TMO #DHR #WST #BDX

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.